npj Vaccines (Oct 2023)

Helper T cell bias following tuberculosis chemotherapy identifies opportunities for therapeutic vaccination to prevent relapse

  • Yazmin B. Martinez-Martinez,
  • Matthew B. Huante,
  • Sadhana Chauhan,
  • Kubra F. Naqvi,
  • Preeti Bharaj,
  • Janice J. Endsley

DOI
https://doi.org/10.1038/s41541-023-00761-4
Journal volume & issue
Vol. 8, no. 1
pp. 1 – 15

Abstract

Read online

Abstract Therapeutic vaccines have promise as adjunctive treatment for tuberculosis (TB) or as preventives against TB relapse. An important development challenge is the limited understanding of T helper (Th) cell roles during these stages of disease. A murine model of TB relapse was used to identify changes in Th populations and cytokine microenvironment. Active TB promoted expansion of Th1, Th2, Th17, and Th22 cells and cytokines in the lung. Following drug therapy, pulmonary Th17 and Th22 cells contracted, Th1 cells remained elevated, while Th cells producing IL-4 or IL-10 expanded. At relapse, Th22 cells failed to re-expand in the lung despite a moderate re-expansion of Th1 and Th17 cells and an increase in Th cytokine polyfunctionality. The dynamics of Th populations further differed by tissue compartment and disease presentation. These outcomes identify immune bias by Th subpopulations during TB relapse as candidate mechanisms for pathogenesis and targets for therapeutic vaccination.